About the Speaker
Dario Marchetti is Professor in the Department of Pathology & Immunology and Director of the CTC Core at Baylor College of Medicine. Dr. Marchetti’s bibliography includes 145 publications, numerous awards, and uninterrupted funding since 1991. He acts as Reviewer of the most relevant journals in cancer research, and on Editorial Boards of “Cancer Microenvironment, “Tumor Viruses”, “Vascular Cell”, “Cancer Letters”, and “Journal of Cellular Biochemistry”, among others. He serves on grant reviewing panels of the National Institutes of Health of USA and Italy, the U.S. Department of Defense, and is a grant Reviewer for other national and international Agencies.AbstractMechanisms of fatal brain metastatic breast cancer (BMBC) are largely unknown. Similarly, properties and biomarker identification of circulating tumor cells (CTCs), the “seeds” of metastasis, remain elusive. Here we report novel strategies investigating CTCs isolated from peripheral blood mononuclear cells (PBMCs) of patients with BMBC, including the development and characterization of CTC lines. We identified a unique BMBC CTC signature (HER2+/EGFR+/HPSE+/Notch1+/EpCAM-) by investigating CTCs that could not be captured by the FDA-approved Veridex CellSearchTM platform (EpCAM - negative CTCs). Second, we analyzed the invasive and metastatic competencies of isolated CTCs. Established CTC lines over-expressing the BMBC signature were highly invasive and capable to form brain metastasis in xenografts. Third, tumor cell morphologies of CTC - induced metastases closely resembled those of pathologically assessed tumors of patients whose blood was source of isolated CTCs. Fourth, the expression of proteins of the BMBC signature was detected in CTC - induced BMBC. Collectively, we provide first-time evidence of human CTCs isolation and long-term growth, the establishment of CTC lines, and CTC metastatic competency in the presence of a biomarker signature necessary to promote BMBC.
The Isolation and Characterization of Brain Metastasis – Competent Breast Cancer CTCs
Video May 02, 2013
About the Speaker
Key concepts discussed in this webinar will include: - Description of the in vitro test systems used to evaluate P-gp and - BCRP inhibition at Sekisui XenoTech and the advantages/disadvantages of these assays - Description of the test system qualification process that takes places prior to offering these assays in definitive studies - Comparison of IC50 values obtained from the different test systems - Comparison of IC50 and Ki values determined with the vesicle test system - How IC50 and Ki values are used to evaluate clinical relevanceWATCH NOW